The focus of this article is an overview of the endothelial changes that in
itiate and perpetuate the process of atherogenesis. The endothelium can und
ergo a series of changes which allow it to participate in the inflammatory
response; this is known as endothelial cell activation (ECA). The five core
changes of ECA are loss of vascular integrity; expression of leucocyte adh
esion molecules; change in phenotype from antithrombotic to prothrombotic;
cytokine production, and upregulation of HLA molecules. The diverse effects
of ECA share a common intracellular control mechanism through the activati
on of the transcription factors including Nuclear Factor kappa B.
ECA is an initiating step in atherogenesis. Modified low density lipoprotei
ns are probably the major cause of endothelial cell activation in atherogen
esis, and become especially so after oxidation, glycation (in diabetes) or
incorporation in immune complexes. In antiphospholipid syndrome (APS), anti
endothelial cell antibodies have been detected in up to 67% of patients. In
vitro studies suggest that aPL causes ECA and thus lead to speculation tha
t aPL by causing ECA may initiate atherogenesis. Further clinical and in vi
tro studies are required to address these issues.